PATH Trial for HHT Published in NEJM!

Published on September 20, 2024

The NIH-Sponsored PATH Trial Becomes First Positive Randomized Clinical Trial for HHT

 

A huge congratulations to the investigators of this trial, the site PIs, coordinators, and importantly, the patients.

 

NIH Press Release

Publication Link (also attached)

NEJM Quick Take Video

nejmoa2312749_plain-language-summary.pdf
NEJM Path Trial.pdf
Other news

Screening Rationale for Children with HHT for Brain VMs

July 14, 2024
'The “watch and wait” approach to imaging means that children with brain vascular malformations will not be identified until a potentially life-threatening and deficit-producing intracerebral hemorrhage occurs. This expert group does not deem this to be an acceptable trade-off.' In this paper, expert providers and advocates review current screening guidelines for children with HHT and provide evid

Vaderis Receives FDA Fast Track Designation for VAD044

November 18, 2024
Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic TelangiectasiaBasel, Switzerland, November 18th, 2024 – Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focusing on treatments for rare diseases associated with vascular malformations, today announces that the US Food and Drug Administration (FDA) has designated the alloster